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With Poor Response to Cardiac
Resynchronization Therapy
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Electroanatomic Contact Mapping and Hemodynamic Study
to Target Endocardial Lead Placement
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ABSTRACT
OBJECTIVES The purpose of this study was to identify the optimal pacing site for the left ventricular (LV) lead in
ischemic patients with poor response to cardiac resynchronization therapy (CRT).
BACKGROUND LV endocardial pacing may offer beneﬁt over conventional CRT in ischemic patients.
METHODS We performed cardiac magnetic resonance, invasive electroanatomic mapping (EAM), and measured the
acute hemodynamic response (AHR) in patients with existing CRT systems.
RESULTS In all, 135 epicardial and endocardial pacing sites were tested in 8 patients. Endocardial pacing was
superior to epicardial pacing with respect to mean AHR (% change in dP/dtmax vs. baseline) (11.81 [-7.2 to 44.6] vs.
6.55 [-11.0 to 19.7]; p ¼ 0.025). This was associated with a similar Q-LV (75 ms [13 to 161 ms] vs. 75 ms [25 to 129 ms];
p ¼ 0.354), shorter stimulation–QRS duration (15 ms [7 to 43 ms] vs. 19 ms [5 to 66 ms]; p ¼ 0.010) and shorter paced
QRS duration (149 ms [95 to 218 ms] vs. 171 ms [120 to 235 ms]; p < 0.001). The mean best achievable AHR was
higher with endocardial pacing (25.64  14.74% vs.12.64  6.76%; p ¼ 0.044). Furthermore, AHR was signiﬁcantly
greater pacing the same site endocardially versus epicardially (15.2  10.7% vs. 7.6  6.3%; p ¼ 0.014) with a shorter
paced QRS duration (137  22 ms vs. 166  30 ms; p < 0.001) despite a similar Q-LV (70  38 ms vs. 79  34 ms;
p ¼ 0.512). Lack of capture due to areas of scar (corroborated by EAM and cardiac magnetic resonance) was associated
with a poor AHR.
CONCLUSIONS In ischemic patients with poor CRT response, biventricular endocardial pacing is superior to epicardial
pacing. This may reﬂect accessibility to sites that cannot be reached via coronary sinus anatomy and/or by access to
more rapidly conducting tissue. Furthermore, guidance to the optimal LV pacing site may be aided by modalities such as
cardiac magnetic resonance to target delayed activating sites while avoiding scar. (J Am Coll Cardiol EP 2016;-:-–-)
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C ardiac resynchronization therapy(CRT) is a highly effective treatmentfor patients with heart failure, severe
left ventricular (LV) impairment and a pro-
longed QRS duration (1–3). Despite advancing
techniques a substantial proportion of indi-
viduals do not derive clinical beneﬁt (4).
Improving CRT response is particularly chal-
lenging in ischemic patients because epicar-
dial LV lead placement within myocardial
scar has a negative impact (5,6) and avoiding
scarred regions may improve CRT response
(7). Furthermore, correction of electrical dys-
synchrony through targeting of the latest point of acti-
vation may be important in improving CRT response
(8,9). Stimulation of the LV endocardium (LVendo),
which is not constrained to the epicardial coronary
venous anatomy, may provide superior hemody-
namics (10–12) and improved CRT response, which
may be of particular beneﬁt in ischemic patients and
nonresponders to conventional CRT (12–14). The site
of optimal LVendo stimulation is highly variable in
ischemic and nonischemic groups (15) with no reliable
method to guide optimal LVendo lead placement. Car-
diacmagnetic resonance (CMR) could potentially iden-
tify the target for LV lead placement, being able to
delineate scar and dyssynchrony (7). Endocardial con-
tact mapping can demonstrate exquisite detail of
endocardial activation as well as location and size of
myocardial scar. Because patients with ischemic car-
diomyopathy and myocardial scar have the poorest
response to CRT and themost to gain fromLVendo pac-
ing, advanced imaging andmappingmodalitiesmay be
able to guide the optimal site for endocardial LV lead
delivery.
Wehypothesized that in a groupof ischemicpatients
(with demonstrable myocardial scar on CMR) and a
high prevalence of CRT nonresponse, LVendo pacing
would produce a superior hemodynamic response
comparedwiththeoptimalepicardial response (LVepi).
Furthermore, by pacing multiple sites, we sought to
investigate whether the optimal site of LV stimulation
(both epicardially and endocardially) could be pre-
dicted on the basis of scar and/or the latest point
of electrical activation. By comparing endocardial
contact mapping data with CMR, we further sought to
elucidate the mechanisms of improved response with
LVendo pacing and whether these imaging modalities
could beused to guide the optimal LVendopacing sites.
METHODS
The study complied with the Declaration of Helsinki
and the protocol was approved by the local ethics
committee. Informed consent was obtained from
each patient. Patients with ischemic cardiomyopathy
(judged by signiﬁcant coronary artery disease and
myocardial ﬁbrosis on CMR), QRS duration of
<150 ms, and previously implanted CRT (mean
duration of implant 26  21 months) have a pheno-
type of suboptimal response to CRT and were inten-
tionally selected for study (3). Baseline assessment
before CRT implant included clinical assessment
(New York Heart Association functional class), 12-lead
electrocardiogram, and 2-dimensional (2D) echocar-
diography. Patients underwent an extensive endo-
cardial mapping protocol and acute hemodynamic
study. CMR data were compared with contact map-
ping and hemodynamic data ﬁndings to compare
optimal LVendo and LVepi pacing locations.
HEMODYNAMIC AND ELECTROANATOMIC STUDY.
Cases were performed under conscious sedation
(mean 2.5 mg midazolam and 3 mg morphine) be-
tween March and December 2014. Patients with a
mechanical aortic valve or signiﬁcant peripheral
vascular disease were excluded. CMR before CRT was
performed with a standardized protocol including
cine imaging and delayed enhancement sequences in
both long and short axis views. Delayed enhancement
was performed 10 to 15 min after administration of
0.2 mmol/kg Gadovist (Bayer Healthcare, Berlin,
Germany) to identify myocardial ﬁbrosis. Contact
LV endocardial scar mapping was performed in sinus
rhythm with a roving decapolar catheter (6-F Live-
wire medium sweep 115 cm; St Jude Medical, Sylmar,
California) via femoral arterial access with a retro-
grade aortic approach and displayed using EnSite
Velocity NavX system (St Jude Medical, Inc, St Paul,
Minnesota). Multiple contact points were taken to
create the endocardial geometry (mean 328  133)
with particular focus of delineating areas of scar.
Points with a sensed bipolar electrogram amplitude
of <0.5 mV were deﬁned as scar and colored grey,
points >1.5 mV were deﬁned as representing healthy
tissue and colored purple and those points in between
deﬁned as border zone with a color range (16).
Temporary placement of a high right atrial quad-
ripolar catheter was used for atrial sensing. Initially,
the optimal epicardial site with atrial synchronous
biventricular pacing was assessed using the patient’s
chronically implanted LV lead (LVepi1) and a second,
temporary epicardial LV lead placed via the femoral
vein (LVepi2) to allow multiple epicardial pacing
sites from different veins and along the same vein
(Figure 1). The optimal endocardial site was then
assessed using the roving LV endocardial decapolar
catheter. The LV was divided into 12 locations
ABBR EV I A T I ON S
AND ACRONYMS
AHR = acute hemodynamic
response
CMR = cardiac magnetic
resonance
CRT = cardiac
resynchronization therapy
EAM = electroanatomic
mapping
LV = left ventricle/ventricular
LVendo = left ventricular
endocardium
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(anterior, lateral, inferior, septal at basal, mid and
apical levels) and randomized (Microsoft Excel). We
planned to pace in each of these 12 regions per pa-
tient; in addition, extra positions in or adjacent to
scar on the EAM were obtained. The mean number of
endocardial positions was 10.4  4.8 (range 4 to 18)
and each patient had a minimum dataset comprising
an anterior, lateral, inferior, and septal position. In all
patients, we performed biventricular pacing at cor-
responding positions endocardially and epicardially
at 2 sites (i.e., LVendo pacing opposite both epi1 and
epi2). We used ﬂuoroscopy (both left anterior oblique
and right anterior oblique views) to show the position
of the decapolar catheter in relation to the implanted
leads and corroborated this with the 3-dimensional
geometric shell on EAM to conﬁrm its anatomic po-
sition with respect to an AHA 16-segment model. We
conﬁrmed the decapolar catheter tip was in a stable,
ﬁxed position before commencing our pacing proto-
col. Prior experience with this equipment has
demonstrated stable electrode localization with mean
change in position of 0.2  1.7 mm (x axis), 0.1  0.3
mm (y axis), and 0.2  0.6 mm (z axis) (17).
The acute hemodynamic response (AHR) was
measured using an 0.014-inch high-ﬁdelity Certus
RADI PressureWire in the LV as previously described
(11). Atrial pacing 10 bpm greater than the intrinsic
rate was used as baseline and compared with con-
ventional epicardial biventricular pacing via the
implanted LV lead (LVepi1), the temporary LV
lead (LVepi2), and biventricular endocardial pacing
(LVendo) at multiple sites. A delay of 20 seconds was
respected after changing the pacing protocol and
before any measurement to allow for a steady state
(18,19). Points either side of an ectopic beat were
removed manually after each case. Atrioventricular
delays were ﬁxed at 100 milliseconds and ven-
triculoventricular delay was set to 0 ms (simulta-
neous stimulation from both right and left ventricular
lead poles). For each pacing site and endocardial po-
sition, we measured LV dP/dtmax (AHR, mm Hg/s),
sensed LV electrogram amplitude (mV), sensed elec-
trical delay (Q-LV) in sinus rhythm (ms), stimulation-
QRS onset (ms), and paced QRS duration (ms). Default
band pass ﬁlter settings of 30 to 300 Hz were used to
measure a sensed, bipolar peak-to-peak voltage signal
for the temporary epicardial LV lead (LVepi2) and
endocardial catheter (LVendo) on the EnSite Velocity
NavX system. The sensed LV signal from the
implanted (LVepi1) lead was obtained through a
printed recording from the pacing systems analyzer
with manual calculation of the peak-to-peak signal.
We identiﬁed whether pacing locations were in or
adjacent to myocardial scar identiﬁed on the EAM and
CMR and measured the distance between the LV tip
and the central scar zone for each data point. Field
scaling was applied to account for impedance anom-
alies and to ensure a 1:1 representation of the pa-
tient’s cardiac geometry (EnSite Velocity NavX
system). An AHR was deemed positive at a pacing
FIGURE 1 Fluoroscopic and Electroanatomic Imaging of the Study Protocol
(A) Fluoroscopic image of the invasive protocol. (B) Corresponding electroanatomic endocardial, contact scar map using a decapolar left
ventricular (LV) catheter and the EnSite Velocity NavX system (St. Jude Medical, Inc., St. Paul, Minnesota); right anterior oblique (left) and left
anterior oblique (right) projections. Data points with a sensed electrogram amplitude of <0.5 mV were deﬁned as scar (grey), those with
voltage of >1.5 mV were deﬁned as healthy tissue (purple) and those points in between were in the scar border zone with a color range.
The anterior surface of the heart in the left panel has been removed to see the location of the endocardial catheter (green) and distal tip
(green circle). The epicardial pacing (LVepi)2 lead is in an anterior vein and displayed in blue on the EAM. In addition, the position of the
implanted (LVepi)1 lead is shown on ﬂuoroscopy and has been superimposed on the electroanatomic map in both views. Epi ¼ epicardial pacing;
HRA ¼ high right atrial; LVEndo ¼ endocardial pacing; RA ¼ right atrial; RADI ¼ LV pressure wire; RV ¼ right ventricular.
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location if the dP/dtmax increased by >10% compared
with baseline measurements (20).
STATISTICAL METHODS. Continuous variables with
a Gaussian distribution were described using mean
values  standard deviation. Categorical data were
described by an absolute number of occurrences and
associated frequency (%). Acute hemodynamic and
electrical data passed the Shapiro-Wilk test for
normality. To account for the clustering of data and
multiple measurements within each patient, a mixed
effect model was applied for all data points that
achieved capture. For the best and worst achievable
AHR per patient, in addition to endocardial opposite
epicardial AHR data, mean differences between
epicardial and endocardial datasets were compared
with a 2-tailed, paired t test. Analysis of variance was
performed to compare the means of several groups.
Results were considered signiﬁcant at p < 0.05.
Analysis was performed on PASW Statistics 22 (SPSS
Inc., Chicago, Illinois) and Stata (Stata Corp., College
Station, Texas).
RESULTS
Mean native QRS duration was 140  7 ms on surface
ECG. Seven patients (88%) were labelled as having
left bundle branch block; however, only 3 (38%) ful-
ﬁlled the stricter Strauss criteria (21). All patients,
however, had evidence of myocardial ﬁbrosis on
CMR. Patient demographics are shown in Table 1.
Procedural time was 160  45 min and there were no
procedural complications. Patients had severe LV
dysfunction with a mean ejection fraction of 27%,
with minimal improvement at 6 months (ejection
fraction 29%). A total of 135 epicardial and endocar-
dial pacing sites were tested in 8 patients, 119 of
which produced capture allowing electrical and he-
modynamic assessment. The remaining 16 data points
did not capture the ventricle at maximal (10 V) output
and were located in regions of scar on the contact
map. The mean number of epicardial pacing sites was
5.8  0.5 and the mean number of LVendo positions
was 10.4  4.8, including sites where LV capture was
unsuccessful.
ACUTE HEMODYNAMIC RESPONSE. Using a mixed
effect model analysis for all data points, the mean
AHR of LVendo positions (11.81% [range -7.2% to
44.6%]) was signiﬁcantly superior to the mean AHR
of LVepi positions (6.55% [range -11.0% to 19.7%];
p ¼ 0.025) (Tables 2 and 3, Online Table, Figure 2).
This was associated with an identical Q-LV between
groups (LVendo 75 ms [range 13 to 161 ms] vs. LVepi
75 ms [range 25 to 129 ms]; p ¼ 0.354) but a shorter
stimulation-QRS duration (LVendo 15 ms [range 7 to
43 ms] vs. LVepi 19 ms [range 5 to 66 ms]; p ¼ 0.010)
and paced QRS duration (LVendo 149 ms [range 95
to 218 ms] vs. LVepi 171 ms [range 120 to 235 ms];
p < 0.001). The mean of the best achievable AHR at
the optimal LVendo site was signiﬁcantly higher than
the optimal LVepi pacing site (25.64  14.74% vs.
12.64  6.76%; p ¼ 0.044). This was associated with
a trend toward a longer Q-LV (95  38 ms vs. 67 
33 ms; p ¼ 0.216), shorter stimulation-QRS duration
(14  5 ms vs. 19  8 ms; p ¼ 0.126) and a shorter
paced QRS duration (137  26 ms vs. 167  33 ms;
p ¼ 0.002). The difference between the best versus
worst LVepi site was highly signiﬁcant (p ¼ 0.0014) as
it was for best versus worst LVendo (p ¼ 0.0002).
There was a greater difference between the best and
worst AHR with LVendo pacing compared with LVepi
pacing 26.57  12.58 vs. 13.44  9.0; p ¼ 0.03.
TABLE 1 Demographic Data, Pre-CRT and Post-CRT Outcomes
(N ¼ 8)
Age (yrs) 71  7.4
Male (%) 8 (100)
LVEF by 2D echocardiography
Simpson’s biplane before CRT
27  7.4
SDI derived from echocardiography (%) 19
NYHA functional class II/III, before CRT implantation 2/6
Ischemic etiology 8 (100)
Sinus rhythm 8 (100)
QRS duration (m) 140  7
LBBB 7 (88)
LBBB by revised Strauss criteria 3 (38)
Echo responders at 6 months* 2 (25)
LVEF by 2D echo, Simpson’s biplane after CRT 29  7.9
Clinical responders at 6 months† 3 (38)
Values are mean  SD or n (%). *Echocardiographic response using 2D trans-
thoracic echocardiography; conﬁrmed if $15% reduction in end-systolic volume
(ESV) at 6 months’ follow-up compared with before implantation. †Clinical
response to CRT using Packer’s clinical composite score (26).
2D ¼ 2-dimensional; CRT ¼ cardiac resynchronization therapy; LBBB ¼ left
bundle branch block; LVEF ¼ left ventricular ejection fraction; NYHA ¼ New York
Heart Association.
TABLE 2 Mixed Effect Model
Mean
Difference
95% Conﬁdence
Interval p Value
Change in AHR (%) 4.23 0.52 to 7.93 0.025
QLV (ms) 5.92 18.45 to 6.60 0.354
Stimulation-QRS duration (ms) 3.70 6.5 to 0.88 0.010
Paced QRS duration (ms) 25.45 33.59 to 17.32 <0.001
Mixed effect model for all data points achieving capture comparing epicardial and
endocardial pacing across the dependent variables as shown. A total of 32
epicardial and 87 endocardial data points were compared across 8 patients.
AHR ¼ acute hemodynamic response; QLV ¼ ﬁrst ventricular depolarization
(earliest onset QRS duration on surface 12 lead electrocardiogram) to the nadir
signal on the LV lead electrogram.
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There was a nonsigniﬁcant trend toward an improved
AHR with basal compared with mid and apical posi-
tions at all sites (LVepi and LVendo) (base 13.7  11,
mid 8.1  9.8, apex 9.6  12.7; p ¼ 0.07).
OPTIMAL LV SITE LOCATION. Epicardial stimulation
sites were limited according to the coronary venous
anatomy and the best achievable epicardial pacing
locations were therefore conﬁned to the AHA seg-
ments subtended by these veins. In 7 of 8 patients,
the optimal LVepi pacing site was inferolateral/
inferior; in the other patient the basal anterior site
was best in keeping with the belief that pacing from
the inferolateral/inferior wall is the optimal site of
epicardial stimulation in the majority of subjects.
LVendo pacing was not limited to the distribution of
the coronary veins and there was substantial indi-
vidual variation in the optimal site producing the best
AHR (Figure 3).
ENDOCARDIAL PACING OPPOSITE EPICARDIAL
LEAD. When the endocardial catheter was placed
opposite the pacing tip of the epicardial lead on the
basis of screening and EAM (Figure 1) (LVepi1/
posterolateral and LVepi2/anterior vein), the AHR
was signiﬁcantly greater (15.2  10.7% vs. 7.6  6.3%;
p ¼ 0.014) despite a similar Q-LV (LVendo 70  38 ms
vs. LVepi 79  34 ms; p ¼ 0.512); however, the paced
QRS duration was signiﬁcantly shorter with LV
endocardial pacing (LVEndo 137  22 ms vs. LVepi
166  30 ms; p < 0.001).
PACING IN SCAR AND LATE ACTIVATED SITES. The
voltage amplitude of the LV sensed electrogram
signal was lower at LVendo compared with LVepi
sites (LVendo 3.84  2.9 mV vs. LVepi 6.68  4.6 mV;
p ¼ 0.002). Of the LVendo stimulation sites, 16 did not
capture and were in scar at a maximal output of 10 V
(conﬁrmed by voltage contact mapping and CMR).
The mean electrogram amplitude within scar sites
with noncapture was 0.18  0.12 mV (n ¼ 16). The
optimal hemodynamic LVendo site was not at the site
of latest electrical activation on the EAM in 6 of 8
patients (Online Table).
DISCUSSION
We studied the optimal site for both LVepi and
LVendo stimulation in a cohort of patients with
ischemic heart disease with poor response to con-
ventional CRT. The principal ﬁndings were as follows.
1. Indiscriminate endocardial pacing was superior to
epicardial stimulation, associatedwith a similarﬁrst
ventricular depolarization, shortened stimulation-
QRS duration and shortened paced QRS duration.
FIGURE 2 Electroanatomic Contact Scar Map With Associated Acute Hemodynamic
Responses During Biventricular Pacing at Different Sites
Anteroposterior (left) and left anterior oblique (right) projections. Data points with a
sensed electrogram amplitude of <0.5 mV were deﬁned as scar (grey), those with voltage
>1.5 mV were deﬁned as healthy tissue (purple), and those points in between were in the
scar border zone with a color range. The best epicardial (LVepi1 and LVepi2) acute he-
modynamic response (% change in dP/dt, mm Hg compared with baseline during biven-
tricular pacing) is displayed alongside 5 endocardial (LVendo) positions. Abbreviations as in
Figure 1.
TABLE 3 Mean Differences Between Epicardial and Endocardial Datasets
Epicardial Endocardial p Value
Best achievable AHRs in
each patient
(N ¼ 8) (N ¼ 8)
Mean change in AHR (%) 12.64  6.76 25.64  14.74 0.044
Mean QLV (ms) 67  33 95  38 0.216
Mean stimulation-QRS
duration (ms)
19  8 14  5 0.126
Mean paced QRS duration (ms) 167  33 137  26 0.002
Worst AHR in each patient (N ¼ 8) (N ¼ 8)
Mean change in AHR (%) 0.80  6.81 0.93  3.79 0.964
Mean QLV (ms) 68  39 59  15 0.556
Mean stimulation-QRS
duration (ms)
26  21 16  4 0.187
Mean paced QRS duration (ms) 174  32 154  34 0.164
Comparison of LVendo opposite
the corresponding position
of LVepi1 and LVepi2
(N ¼ 16) (N ¼ 16)
Mean change in AHR (%) 7.60  6.3 15.2  10.7 0.014
Mean QLV (ms) 79  34 70  38 0.512
Mean stimulation-QRS
duration (ms)
20  13 16  7 0.214
Mean paced QRS duration (ms) 166  30 137  22 <0.001
Values are mean  SD.
LVendo¼ endocardial pacing; LVepi¼ epicardial pacing; other abbreviations as in Tables 1 and 2.
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2. Optimal achievable endocardial AHR was superior
to the optimal achievable epicardial AHR.
3. There was signiﬁcant interindividual variability of
the position of the optimal LVendo site which was
not predicted by the site of latest electrical acti-
vation on EAM.
4. Pacing within scar on EAM and CMR (both epicar-
dial and endocardial positions) resulted in failure
to capture and a poor AHR.
5. LVendo stimulation at a site approximating LVepi
stimulation resulted in a better AHR and shorter
paced QRS duration despite a similar Q-LV.
COMPARISON WITH PREVIOUS STUDIES. In keeping
with the current study, LVendo pacing has been
found to be superior to conventional CRT in both
ischemic and nonischemic patients (11–13). Derval
et al. (22) found that LVendo pacing was superior to
posterolateral LVepi pacing in nonischemic patients
with signiﬁcant individual variation between the
optimal LVendo pacing sites (22). Spragg et al. (10)
undertook EAM and AHR measurement in 11 pa-
tients with ischemic heart disease and dyssynchro-
nous heart failure at the time of ventricular
tachycardia ablation and found LVendo was superior
to LVepi pacing (10). Our group has shown the supe-
riority of LVendo pacing over conventional CRT in a
group of ischemic and nonischemic patients (11). The
superiority of LVendo pacing over LVepi seems to be
reproducible, but with a signiﬁcant variability in the
optimal site between patients in all the aforemen-
tioned studies (10–12).
The current study has some important differences
and new ﬁndings in comparison with previous
studies that may be of clinical importance. First, our
subjects were selected on the basis of having factors
associated with a suboptimal response to conven-
tional CRT, namely, male sex, ischemic cardiomyop-
athy, myocardial ﬁbrosis (on CMR), and a QRS
duration of 120 to 150 ms. Although all patients were
ischemic in the study by Spragg et al. (10), our sub-
jects had a narrower QRS duration (140  14.9 ms vs.
176  29 ms). In the prior studies, epicardial biven-
tricular pacing was only delivered from a single site in
the posterolateral vein. The superiority of LVendo in
these studies (10–12) may have, therefore, arisen
because the optimal LVepi position was not assessed.
In the current study, we rigorously performed
epicardial pacing from multiple sites (between and
along veins) to ﬁrst determine the optimal LVepi site
(mean 5.8  0.5 sites per subject). For the ﬁrst time
our ﬁndings conﬁrm the superiority of LVendo stim-
ulation, when both LVendo and LVepi sites are sys-
tematically optimized. Figure 2 shows an example of
the superiority of LVendo over LVepi pacing even
when LVepi pacing produced a good AHR.
A notable ﬁnding of the current study was the
superiority of LVendo over LVepi at the same site.
Previous studies have suggested no difference in
ischemic and nonischemic patients, however we
FIGURE 3 The Optimal Site for LV Stimulation During Biventricular Pacing
Optimal endocardial (left) and epicardial (right) sites (by acute hemodynamic response [AHR]) for placement of the LV lead in the 8 patients.
Black circles with a yellow circumference represent the best overall location (LVendo vs. LVepi). This demonstrates that in 6 patients, LVendo
pacing produced the best AHR and the optimal locations were dispersed throughout the geometry of the LVendo. Two patients had the best
AHRs achieved with LVepi pacing; as can be seen the pacing locations were clustered due to the constraints of the epicardial veins. AHA ¼
American Heart Association; ANT ¼ anterior; ANT LAT ¼ anterior lateral; POST ¼ posterior; POST LAT ¼ posterior lateral; SEPT ¼ septal; other
abbreviations as in Figure 1.
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found a signiﬁcant beneﬁt with endocardial pacing
(15.2  10.7% vs. 7.6  6.3%; p ¼ 0.014). Spragg et al.
(10) compared LVendo and LVepi at the same site in 7
patients and found LVendo pacing increased dP/dtmax
by 36% from baseline compared with 29% via LVepi
although this increase was not statistically signiﬁ-
cant. These differences may be related to the
different population studied, but also that we
assessed and optimized LVepi pacing in both the
anterior and posterolateral regions. Our data are in
keeping with both animal studies (13) and a computer
modelling study from our group (14). Finally, our
patients had CMR data that could be correlated with
the results of EAM, which was not the case in the
aforementioned studies (Figure 4).
SCAR AND ELECTRICAL ACTIVATION. In the study
from Spragg et al. (10), optimal LVendo pacing sites
typically were located far from regions of dense scar
and in 8 of 11 subjects optimal LVendo sites were not
at the site of latest activation. For most patients,
optimal pacing sites were located in regions activated
neither extremely early nor late during ventricular
excitation. The authors concluded the lack of corre-
lation between latest endocardial activation sites and
optimal pacing sites may reﬂect a disconnect between
electrical and mechanical activation, the impact of
regions of slow conduction, and lines of conduction
block on optimal pacing sites. Our results support this
theory, conﬁrmed by failure to capture the LV at
maximal voltage at 16 endocardial sites within scar
(on CMR and EAM). Furthermore, the optimal hemo-
dynamic LVendo site did not necessarily correlate
with the site of latest electrical activation in 6 of 8
patients, as determined on the EAM activation map.
In keeping with this ﬁnding, the Q-LV at the optimal
LVendo sites were not signiﬁcantly longer than those
at the optimal LVepi site. It seems likely that, on the
basis of our and other prior ﬁndings, the latest acti-
vating site is not necessarily the optimal site to pace
with respect to improved hemodynamics. This may
be due to localized areas of slow conduction with
islands of viable tissue within areas of scar that acti-
vate late (and therefore have a long Q-LV). Likewise,
when stimulation is performed at that site, impulse
propagation is also slow out of this area and does not
FIGURE 4 Local Activation Map, Correlation With Myocardial Fibrosis on CMR and Associated AHR at Different Locations in 1 Patient
(Top) Electroanatomic (EAM) contact map showing local activation in the same subject as in Figure 2. White signiﬁes earliest activation and
blue latest activation, demonstrating the basal lateral region as the site of latest electrical delay. In this case, the optimal AHR (star) matched
the site of latest electrical delay, which was distant from ischemic scar. (Bottom) Cardiac MR (CMR), late gadolinium enhancement sequences in
the short axis, mid ventricular (left), 2-chamber (middle), and 4 chamber (right) views. The white arrows demonstrate areas of thin walled
myocardium with associated subendocardial myocardial ﬁbrosis, corresponding to an left anterior descending (LAD) territory myocardial
infarction. There is a close correlation between the scar demonstrated on the EAM and that displayed with CMR. (Right) AHA bulls-eye plot
diagram with scar (derived from CMR and EAM) spray painted in grey (anterior, LAD infarct). All different positions for the LV lead are
demonstrated (both epicardial and endocardial) with the legend detailing whether the associated AHR with biventricular pacing was <10% or
>10% improvement from baseline. Pacing around the anterior regions of scar corresponded to a poor AHR, compared with much better AHRs in
sites out of scar. Abbreviations as in Figures 1 and 3.
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result in effective resynchronization. An example of
this is seen in Figure 5 in a patient with a large
circumferential midventricular and apical infarct with
areas of late activating tissue within the scar. It is
possible that seeking a late activated site may be
beneﬁcial, but only if conduction out of that site is
not also delayed or blocked by regions of scar. This is
analogous to a Goldilocks effect where the optimal
site in ischemic patients because of scar/slow con-
duction may be not too early, not too late but just
right, somewhere in between the two.
MECHANISM OF BENEFIT OF LVendo PACING. In-
discriminate stimulation of the LVendo produced a
superior hemodynamic effect compared with con-
ventional epicardial stimulation. The beneﬁt of
LVendo pacing may be related to the lack of coronary
venous constraints and the ability to access all re-
gions of the myocardium resulting in the ability to
obtain the best achievable AHR. The broad variation
in hemodynamic response and notable lack of capture
in areas of scar, clearly visible on CMR/EAM suggest a
targeted approach avoiding scar may be helpful.
The superiority of the optimal LVendo over the
optimal LVepi AHR at the same site with an associ-
ated shorter paced QRS duration may support more
rapid activation of the ventricles by fast conducting
tissue including the His-Purkinje network (14,15).
Equally, other mechanisms (not examined in this
manuscript) such as a shorter, more concave path for
electrical conduction with LVendo pacing may also be
contributing to our ﬁndings.
CLINICAL RELEVANCE. CRT nonresponse occurs in
one-third of patients receiving this treatment and is
higher in ischemic patients with myocardial ﬁbrosis
and modest QRS prolongation (120 to 150 ms). Stra-
tegies to improve response in this group are required.
The recently published ALSYNC (ALternate Site Car-
diac ResYNChronization) study demonstrated the
feasibility and safety of LV endocardial CRT deliv-
ered, through the atrial trans-septal approach (23). In
138 patients with either prior suboptimal response to
conventional CRT, failure of LV lead implantation or
suboptimal coronary venous anatomy the in-
vestigators achieved a high implant success rate
(89.4%), with stable pacing parameters and an 82.2%
freedom from complications at 6 months. Further-
more, clinical and echocardiographic improvement
was 59% and 55%, respectively, in a group with prior
nonresponse, which is highly encouraging. Targeting
the optimal site for LV stimulation remains an
important issue given the marked degree of variability
between patients. Our results suggest that CMR may
be helpful in this respect especially in avoiding areas
of scar, which result in failure to capture or poor
FIGURE 5 Local Activation Map and Associated Acute Hemodynamic Response in a Patient With Electrical Latency Within a
Large Area of Scar
Dilated, globular heart with a heavy burden of myocardial scar. Earliest activation is white and latest activation blue/purple. In this case,
LVendo locations were not superior to conventional LVepi with respect to the AHR. The point of latest electrical activation in this case is around
the anteroseptum, most likely as a result of slow activation spreading and encircling a large region of scar. Although these sites are the latest
activated they will not produce a good AHR because they are in scar and may explain why the latest activated site is not always the optimal
pacing site. Abbreviations as in Figures 1 and 3.
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resynchronization. Targeting a late but not necessarily
latest activating site (i.e., late but not within the scar)
is achievable with CMR techniques that give infor-
mation regarding myocardial activation/contraction
patterns as well as pinpointing scar (24).
The ALSYNC study used an empirical approach to
LV lead placement and despite this reported a sig-
niﬁcant improvement compared with conventional
epicardial pacing. Our results support image guidance
on the basis that a broad range of AHR values were
obtained and therefore not all endocardial positions
are equal in this cohort. Although an indiscriminate
approach showed endocardial pacing was superior to
epicardial pacing (Table 2), an even greater AHR was
achievable when both epicardial and endocardial
sites were optimized. Therefore, an image-guided,
targeted approach could be a strategy for identifying
the optimal location for LV lead stimulation. CMR
techniques do, however, require further evaluation to
assess their merit in guiding endocardial pacing sites
and techniques which allow CMR derived scar and
mechanical activation to be fused onto live ﬂuoros-
copy for epicardial LV lead guidance may also be used
for LVendo lead guidance (18,25).
STUDY LIMITATIONS. The main limitation of the
current study is the low number of patients studied.
Due to the highly invasive nature of the study and the
difﬁculty in identifying a group of nonresponders,
this is understandable. The protocol was, however,
extremely rigorous with a large number of data points
(135 endocardial and epicardial pacing positions). The
EAM study is invasive and not likely to be of use in
routine clinical practice. Due to the length of the
procedures no changes in atrioventricular or ven-
triculoventricular delay were studied and it is
possible that such manipulations may have produced
a different response. Finally, hemodynamic response
may not necessarily translate to chronic response to
CRT and therefore longer term studies are required;
results from a multicenter, randomized, controlled
trial, RADI-CRT (Pressure Wire Guided Cardiac
Resynchronisation Therapy) (NCT01464502) may
help to clarify this.
CONCLUSIONS
Our ﬁndings suggest that, in ischemic patients with
poor CRT response, endocardial pacing is superior to
epicardial pacing with an even greater response
achievable with optimization for each set of pro-
tocols. The mechanism of beneﬁt may be due to the
ability to access more optimal sites that cannot be
reached by the constraints of the CS anatomy.
Furthermore, guidance to the optimal LV pacing site
may be aided by modalities such as CMR to target
nonscarred and delayed activating sites.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Biventricular
pacing delivered through LV endocardial stimulation seems to
provide superior acute hemodynamics and a shortening of the
paced QRS duration compared with LV epicardial stimulation in
the equivalent territory. A lack of coronary venous constraint and
preferential access to fast conducting tissue are likely to under
pin the superiority of this method for delivery of CRT. Cardiac
magnetic resonance–derived myocardial ﬁbrosis corroborates
with scar derived from electroanatomic maps and may be helpful
in guiding LV lead placement. Furthermore, targeting nonscarred
segments identiﬁed through cardiac magnetic resonance cine
sequences can aid optimal lead placement in an attempt to
improve response to CRT.
TRANSLATIONAL OUTLOOK: Biventricular pacing has been
offered to selected patients with heart failure for more than 20
years; however, a signiﬁcant proportion of individuals receiving
this therapy do not derive signiﬁcant clinical beneﬁt. Certain
groups such as male patients with ischemic etiology, myocardial
scar and QRS duration of 120 to 150 ms have a high prevalence
for poor response and alternative options for improving the
effectiveness of CRT are urgently required. Recently, animal and
human data have suggested superior hemodynamics and shorter
electrical activation for endocardial versus epicardial LV stimu-
lation in delivery of biventricular pacing. Clinical studies have
demonstrated the feasibility of endocardial LV stimulation
through transatrial septal and transventricular septal ap-
proaches, as well as leadless LV pacing in combination with an
implanted right-sided system. Coupled with advanced cardiac
imaging to guide LV placement away from areas of scar and to-
ward those activating lately, CRT delivery through permanent LV
endocardial stimulation may represent a new method to improve
outcomes for heart failure patients over the coming decades.
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